<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Introduction Treatment of" exact="leishmaniasis" post="with conventional synthetic drugs is a major global challenge."/>
 <result pre="the WHO around 12 million people are currently infected with" exact="leishmaniasis" post="in 98 countries, over one billion people are at"/>
 <result pre="of the disease are diverse, although two classical forms including" exact="visceral leishmaniasis" post="(VL or kala-azar) and cutaneous form (CL) are predominant"/>
 <result pre="the disease are diverse, although two classical forms including visceral" exact="leishmaniasis" post="(VL or kala-azar) and cutaneous form (CL) are predominant"/>
 <result pre="low OD or IC50 values. Recent global data indicate that" exact="leishmaniasis" post="has become a major medical and veterinary health concern"/>
 <result pre="J. Trop. Biomed.52015695701 BahramiS.KhademvatanS.Razi JalaliM.H.PourbaramS.Amiodarone triggers induction of apoptosis in" exact="cutaneous leishmaniasis" post="agentsPathogens and global health.110201620020427553974 BajajS.WakodeS.R.KhanW.ManchandaS.KumarS.Simultaneous HPTLC analysis and in"/>
 <result pre="Trop. Biomed.52015695701 BahramiS.KhademvatanS.Razi JalaliM.H.PourbaramS.Amiodarone triggers induction of apoptosis in cutaneous" exact="leishmaniasis" post="agentsPathogens and global health.110201620020427553974 BajajS.WakodeS.R.KhanW.ManchandaS.KumarS.Simultaneous HPTLC analysis and in"/>
 <result pre="major promastigotesJournal of evidence-based complementary &amp;amp; alternative medicine222017313626747836 NoazinS.ModabberF.KhamesipourA.SmithP.G.MoultonL.H.NasseriK.First generation" exact="leishmaniasis" post="vaccines: a review of field efficacy trialsVaccine.2620086759676718950671 RochaL.G.AlmeidaJ.MacedoR.O.Barbosa-FilhoJ.M.A review"/>
</results>
